+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chagas Disease (American trypanosomiasis) Drug Development Pipeline Study, H2 2018

  • ID: 4604862
  • Report
  • Region: United States
  • 70 pages
  • VPA Research
UP TO OFF
until Sep 30th 2019
1 of 3
Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical Studies

FEATURED COMPANIES

  • Bayer AG
  • Daiichi Sankyo Co Ltd
  • Eisai Co Ltd
  • Johnson & Johnson Ltd
  • Kancera AB
  • Novartis AG
  • MORE
Chagas Disease (American trypanosomiasis) Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Chagas Disease (American trypanosomiasis) pipeline products.

DISEASE OVERVIEW:

Chagas disease, also known as American Trypanosomiasis, is one of the catastrophic infectious diseases worldwide. An estimated 0.3 million people die from Chagas disease while 8 million+ people are affected annually. The disease presence is determined through microscopic examination of blood smears.

The parasite Trypanosoma cruzi is responsible for spreading this disease. Triatomine bug spreads this disease while sucking blood of humans or animals. Further, blood transfusion, organ transplantation, congenital transmission can be other factors for acquiring Chagas disease.

Due to the strong potential for treatment options for Chagas disease, 10 companies are intensively working on developing new pipeline products. The products under development include both vaccines and treatment options.

Both leading pharmaceutical companies and medium sized players are actively participating in pre-clinical and clinical studies of Chagas disease. The list of companies includes- Bayer AG
Collaborations Pharmaceuticals, Daiichi Sankyo Co Ltd, Eisai Co Ltd, Johnson & Johnson, Kancera AB, Novartis AG, Oblita Therapeutics BVBA, RIKEN, Sanofi, Vyera Pharmaceuticals.

REPORT DESCRIPTION:

The Chagas Disease (American trypanosomiasis) pipeline guide presents complete overview of drugs currently being developed for Chagas Disease (American trypanosomiasis). The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Chagas Disease (American trypanosomiasis) pipeline candidate.
Research and Development progress along with latest news related to each of the Chagas Disease (American trypanosomiasis) pipeline candidates is included.

Major companies participating in therapeutic development of Chagas Disease (American trypanosomiasis) are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Chagas Disease (American trypanosomiasis) from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Chagas Disease (American trypanosomiasis) clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Chagas Disease (American trypanosomiasis) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

Scope of Chagas Disease (American trypanosomiasis) pipeline report includes:
  • Panorama of Chagas Disease (American trypanosomiasis) pipeline markets including statistics on therapeutic drugs and companies involved
  • Chagas Disease (American trypanosomiasis) Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
  • Chagas Disease (American trypanosomiasis) pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
  • Overview of companies participating in Chagas Disease (American trypanosomiasis) pipeline with short introduction to their businesses and pipeline projects
  • For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
  • Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Chagas Disease (American trypanosomiasis) pipeline therapeutics
Reasons to Buy:
  • Get clear understanding of the entire Chagas Disease (American trypanosomiasis) pipeline, with details on active projects
  • Get in detail information of each product with updated information on each project along with key milestones
  • Know the list of companies participating in global Chagas Disease (American trypanosomiasis) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Bayer AG
  • Daiichi Sankyo Co Ltd
  • Eisai Co Ltd
  • Johnson & Johnson Ltd
  • Kancera AB
  • Novartis AG
  • MORE
I. Key Findings

1. Companies Investing in Chagas Disease Pipeline include-
Number of Companies with Chagas Disease projects in pre-clinical Development-
Number of Companies with Chagas Disease projects in Clinical Development-
Chagas Disease Pipeline Companies based in Americas
Chagas Disease Pipeline Companies based in Europe
Chagas Disease Pipeline Companies based in Asia Pacific
Chagas Disease Pipeline Companies based in Rest of the World

2. Pipeline Candidates include-
Chagas Disease Pipeline Agents in pre- clinical/ Discovery stage of Development
Chagas Disease Pipeline Agents in Clinical Development stage
Chagas Disease Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Chagas Disease Pipeline agents

II. Insights into Chagas Disease Pipeline

1. Disease Overview
Introduction to Chagas Disease
Symptoms and Causes of Chagas Disease
Treatment or Prevention Options for Chagas Disease
Other Details
2. Phase wise Pipeline Compounds
Chagas Disease Pipeline- Pre- Clinical/ Discovery stage Drugs
Chagas Disease Pipeline- Phase 1 stage Drugs
Chagas Disease Pipeline- Phase 2 stage Drugs
Chagas Disease Pipeline- Phase 3 stage Drugs
Chagas Disease Pipeline- Pre-Registration stage Drugs
3. Company wise Chagas Disease Pipeline Compounds
4. Chagas Disease Pipeline by Mechanism of Action

III. Chagas Disease Pipeline Compound Details
  • nifurtimox
  • Pyronaridine
  • Drug for Chagas Disease
  • fosravuconazole
  • infectious disease therapeutics
  • KAN0441411
  • GNF6702
  • D121
  • MAO-1
  • Fexinidazole
  • SAR114137
  • TRP-012
Drug Details

1. Snapshot-
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. Chagas Disease Pipeline Company Briefs
  • Bayer AG
  • Collaborations Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • Eisai Co Ltd
  • Johnson & Johnson Ltd
  • Kancera AB
  • Novartis AG
  • Oblita Therapeutics BVBA
  • Sanofi SA
  • Vyera Pharmaceuticals AG
V. Latest News and Developments in Global Chagas Disease Pipeline Market

VI. Appendix
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Bayer AG
  • Collaborations Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • Eisai Co Ltd
  • Johnson & Johnson Ltd
  • Kancera AB
  • Novartis AG
  • Oblita Therapeutics BVBA
  • Sanofi SA
  • Vyera Pharmaceuticals AG
Note: Product cover images may vary from those shown
Adroll
adroll